In a study of front-line providers, the psychedelic drug reduced symptoms of depression more effectively than a placebo.
Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care in 2020 and 2021. These reductions were measurably greater than those experienced by the cohort of clinicians who received a placebo instead.
Findings from this double-blind, randomized clinical trial were published December 5, 2024 in JAMA Network Open.
Comments